Universitätsmedizin Rostock

Running trials

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Source

• Not yet recruiting

  Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

  NCT07234877· Phase 2· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Source

• Recruiting

  FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

  NCT07674667· Phase 1/2· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Source

• Recruiting

  A Randomized Phase 1 / 2 Trial Aiming to Restore UNC13A Function in People living with ALS: FUNCtion ALS

  2025-523111-11-00· Phase 1/2· Source

• Recruiting

  Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

  NCT07333066· Phase 3· Source

• Recruiting

  PREFer

  NCT06916416· Phase 2· Source

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Source

• Not yet recruiting

  Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).

  2025-523672-23-00· Phase 2· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Source

• Recruiting

  A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07571174· Phase 1· Source

• Recruiting

  Improved Management of Patients With Recent-Onset Stable Chest Pain

  NCT07476040· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Source

• Recruiting

  A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT07225569· Phase 2· Source

• Recruiting

  Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.

  2024-512503-39-00· Phase 4· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

  NCT06804161· Phase 3· Source

• Recruiting

  Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

  NCT07038356· Phase 3· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Not yet recruiting

  A Phase 2 Trial Evaluating the Effects of Thiethylperazine as diagnostic tool and therapeutic agent in Patients Diagnosed with an Early Stage of Alzheimer's disease

  2022-501137-23-00· Phase 2· Source

• Recruiting

  A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Phase 3· Source

• Recruiting

  A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

  NCT07227402· Phase 3· Source

• Recruiting

  PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA

  2024-512922-27-00· Phase 2· Source

• Recruiting

  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

  NCT07026474· Phase 3· Source

• Recruiting

  Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

  NCT07151378· Phase 3· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Source

• Recruiting

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· Phase 3· Source

• Recruiting

  Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

  NCT07023835· Phase 2· Source

• Recruiting

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Phase 3· Source

• Recruiting

  A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07100119· Phase 1· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

  2023-510356-23-00· Phase 1· Source

• Active, not recruiting

  A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT07047118· Phase 2· Source

• Not yet recruiting

  Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System and verteporfin for injection for the treatment of primary localized prostate cancer

  2024-519658-35-00· Phase 1/2· Source

• Recruiting

  Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

  NCT06717958· Phase 2· Source

• Recruiting

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· Phase 3· Source

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Source

• Active, not recruiting

  A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT06795048· Phase 4· Source

• Recruiting

  IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

  NCT06713837· Phase 3· Source

• Recruiting

  Cyclosporine In Takotsubo Syndrome

  NCT05946772· Phase 2· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· Source

• Active, not recruiting

  A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) study

  2024-512338-13-00· Phase 1· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

  NCT06643481· Phase 2· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Source

Showing 50 of 110.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• Prostate cancer8 recruiting
• ALS (motor neurone disease)6 recruiting
• Acute myeloid leukaemia5 recruiting
• Lung cancer5 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Colorectal cancer3 recruiting
• Coronary artery disease3 recruiting
• Crohn's disease3 recruiting
• Myelodysplastic syndromes3 recruiting
• Sarcoma3 recruiting
• Ulcerative colitis3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Alzheimer disease2 recruiting
• Atrial fibrillation2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Kidney cancer2 recruiting
• Mantle cell lymphoma2 recruiting
• Pancreatic cancer2 recruiting
• Parkinson disease2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bladder cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• Hidradenitis suppurativa1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Macular degeneration1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Myocarditis1 recruiting
• Neuroblastoma1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting
• Vascular dementia1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT07571200· Phase 1· Source

• Active, not recruiting

  NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

  NCT06379217· Phase 1· Source

• Terminated

  A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

  NCT06220669· Phase 2· Source

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· Source

• Completed

  Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)

  2022-503148-41-00· Phase 2· Source

• Completed

  Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy

  2022-502208-64-00· Phase 2· Source

• Completed

  A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-505558-16-00· Phase 3· Source

• Completed

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· Phase 2· Source

• Terminated

  Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

  NCT04854096· Phase 2· Source

• Completed

  Extension Study Evaluating The Safety And Tolerability of AMX0035

  NCT05619783· Phase 3· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Completed

  Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours

  2024-511071-16-00· Phase 1· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Source

• Completed

  A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis

  NCT05021536· Phase 3· Source

• Terminated

  Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

  NCT05028569· Phase 3· Source

• Completed

  Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

  NCT04813627· Source

• Completed

  177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

  NCT04689828· Phase 3· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Source

• Completed

  Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04833114· Phase 3· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Completed

  Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

  NCT03399513· Phase 2· Source

• Completed

  Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

  NCT03463317· Phase 4· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Completed

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· Phase 3· Source

• Completed

  HD21

  NCT02661503· Phase 3· Source

• Completed

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Phase 2· Source

• Completed

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· Source

Trial sites

• Rostock University Medical Center110 trials
• Universitaetsmedizin Rostock6 trials
• Universitaetsmedizin Rostock /ID# 1283961 trial
• Universitaetsmedizin Rostock /ID# 2241571 trial
• Universitaetsmedizin Rostock /ID# 2254360 trials
• Universitaetsmedizin Rostock /ID# 2301900 trials
• Universitaetsmedizin Rostock /ID# 2324711 trial
• Universitaetsmedizin Rostock /ID# 2372630 trials
• Universitaetsmedizin Rostock /ID# 2596571 trial
• Universitaetsmedizin Rostock /ID# 2783010 trials
• Universitaetsmedizin Rostock - Medizinische Klink III (Hamatologie, Onkologie, Palliativmedizin)0 trials
• Universitätsmedizin Rostock14 trials
• Universitätsmedizin Rostock, Herzzentrum, Zentrum Innere Medizin - Abteilung für Kardiologie1 trial
• Universitätsmedizin Rostock, Institut für Allgemeinmedizin1 trial
• Universitätsmedizin Rostock, Institut für Diagnostische und Interventionelle Radiologie, Kinder- und Neuroradiologie1 trial
• Universitätsmedizin Rostock, Rostock Medical Faculty, Dept. of Urology1 trial
• Universitätsmedizin Rostock (Site 0993)0 trials
• Universitätsmedizin Rostock, Zentrum für Innere Medizin, Abteilung für Kardiologie1 trial
• Universitätsmedizin Rostock, Zentrum Innere Medizin, Abteilung Kardiologie0 trials
• University Medical Center Rostock4 trials

Conditions

Diseases this institution publishes on or runs trials for.

• ALS (motor neurone disease)17 works · 12 trials
• Head and neck cancer13 works · 6 trials
• Frontotemporal dementia7 works · 0 trials